UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

International journal of molecular sciences, 2022-02, Vol.23 (5), p.2668

2022

Volltextzugriff (PDF)

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

Journal of hepatology, 2020-10, Vol.73 (4), p.757-770

2020

Volltextzugriff (PDF)

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis

Gut, 2020-03, Vol.69 (3), p.551-563

2020

Volltextzugriff (PDF)

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

PloS one, 2017-09, Vol.12 (9), p.e0184694-e0184694

2017

Volltextzugriff (PDF)

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression

International journal of molecular sciences, 2023-03, Vol.24 (6), p.5295

2023

Volltextzugriff (PDF)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

International journal of molecular sciences, 2022-06, Vol.23 (12), p.6696

2022

Volltextzugriff (PDF)

Monocyte dysregulation: consequences for hepatic infections

Seminars in immunopathology, 2021-08, Vol.43 (4), p.493-506

2021

Volltextzugriff (PDF)

CT-based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients

PloS one, 2021-04, Vol.16 (4), p.e0250321-e0250321

2021

Volltextzugriff (PDF)

The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis

Journal of clinical medicine, 2020-04, Vol.9 (4), p.1140

2020

Volltextzugriff (PDF)

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Expert opinion on investigational drugs, 2023-06, Vol.32 (6), p.451-461

2023

Volltextzugriff (PDF)

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Expert opinion on pharmacotherapy, 2024-06, Vol.25 (9), p.1-1263

2024

Volltextzugriff (PDF)

Repair macrophages in acute liver failure

Gut, 2018-02, Vol.67 (2), p.202-203

2018

Volltextzugriff (PDF)

Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial

Journal of global antimicrobial resistance., 2023-03, Vol.32, p.44-47

2023

Volltextzugriff (PDF)

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Journal of hepatology, 2023-08, Vol.79 (2), p.552-566

2023

Volltextzugriff (PDF)

Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients

Diagnostics (Basel), 2020-11, Vol.10 (11), p.990

2020

Volltextzugriff (PDF)

Efruxifermin, an investigational treatment for fibrotic or cirrhotic non-alcoholic steatohepatitis (NASH)

Expert opinion on investigational drugs, 2023-06

2023

Volltextzugriff (PDF)

Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients

Diagnostics (Basel), 2021-12, Vol.12 (1), p.62

2021

Volltextzugriff (PDF)

THU-291-YI Cellular senescence is a common hallmark in diverse models of steatotic liver diseases

Journal of hepatology, 2024-06, Vol.80, p.S594-S595

2024

Volltextzugriff (PDF)

FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis

Journal of hepatology, 2024-06, Vol.80, p.S414-S414

2024

Volltextzugriff (PDF)

Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis

Expert review of endocrinology & metabolism, 2022-09, Vol.17 (5), p.425-434

2022

Volltextzugriff (PDF)

Acquisition of epithelial plasticity in human chronic liver disease

Nature (London), 2024-06, Vol.630 (8015), p.166-173

2024

Volltextzugriff (PDF)

PS-007-Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis

Journal of hepatology, 2019-04, Vol.70 (1), p.e8-e9

2019

Volltextzugriff (PDF)

Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Journal of hepatology, 2020-08, Vol.73, p.S13

2020

Volltextzugriff (PDF)

AS016 - Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Journal of hepatology, 2020-08, Vol.73, p.S13-S13

2020

Volltextzugriff (PDF)

Diagnostik und Therapie der schweren akuten Pankreatitis in der Intensivmedizin

Deutsche medizinische Wochenschrift, 2020-06, Vol.145 (12), p.850-862

2020

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(28)

Sprache

Englisch
(25)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages

Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

Monocyte dysregulation: consequences for hepatic infections

CT-based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients

The Medium-Chain Fatty Acid Receptor GPR84 Mediates Myeloid Cell Infiltration Promoting Steatohepatitis and Fibrosis

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Repair macrophages in acute liver failure

Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients

Efruxifermin, an investigational treatment for fibrotic or cirrhotic non-alcoholic steatohepatitis (NASH)

Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients

THU-291-YI Cellular senescence is a common hallmark in diverse models of steatotic liver diseases

FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis

Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis

Acquisition of epithelial plasticity in human chronic liver disease

PS-007-Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis

Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

AS016 - Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis

Diagnostik und Therapie der schweren akuten Pankreatitis in der Intensivmedizin

Aktive Filter

Suchergebnisse filtern